Renowned Specialists to Support Development of Delenex' Advancing Pipeline

Schlieren/Zurich, Switzerland - 21 July 2014 - Delenex Therapeutics AG, a clinical-stage biopharmaceutical company primarily developing treatments for dermatologic diseases using its proprietary PENTRA^(R)Bodies, today announced the establishment of an advisory board of seasoned executives and scientists. Seven world-renowned specialists will bring strong clinical, scientific and drug formulation expertise and assist in developing and implementing Delenex R&D strategy.

The members of the advisory board are:

Michael Detmar, M.D., Professor of Pharmacogenomics at the ETH Zurich, Switzerland. Professor Detmar is Dermatologist by training; his research work has led to a fundamental understanding of angiogenesis in skin inflammatory disorders.

Peter Elias, M.D., Professor of Dermatology at the UCSF, San Francisco, CA, USA. Prof. Elias has analyzed in depth over decades the function of the stratum corneum of the skin resulting in a novel understanding on this part of the skin.

Richard Guy, Ph.D., Professor of Pharmaceutical Sciences at the University of Bath, UK. Prof. Guy's research focuses on skin barrier function characterization, dermal drug delivery and the assessment of skin penetration.

James G. Krueger, M.D., Ph.D., Professor of Dermatology at The Rockefeller University, New York, NY, USA. Prof. Krueger has done groundbreaking analyses on the regulation of immune pathways in psoriatic skin.

Thomas Luger, M.D., Ph.D., Professor of Dermatology and Chairman of the Department of Dermatology, and also the Director of the Institute of Cell Biology and Immunobiology of the Skin at Münster University, Germany. Prof. Luger's clinical interest is focused on allergic inflammation and autoimmune diseases of the skin.

Georg Stingl, M.D., Professor and Chairman of Dermatology, Division of Immunology, Allergy & Infectious Diseases (DIAID), Department of Dermatology, Medical University of Vienna, Austria. Prof. Stingl brings extensive experience in the regulation of skin immunology by dendritic cells and in clinical development.

Gerhard Winter Ph.D., Professor of Pharmaceutical Technology and Biopharmacy at the University of Munich, Germany. Prof. Winter's extensive expertise is in the field of formulating proteins.

Thomas Jung, CMO at Delenex, said: "I am very much looking forward to have the opportunity to work with these prestigious experts on the further development of Delenex' pre- and clinical products".

"We are delighted and honored to have these internationally acknowledged leaders in dermatology and skin physiology join our advisory board," added Thomas Hecht, Delenex Therapeutics' Executive Chairman. "Their expertise in skin immunology and physiology will be instrumental in advancing our therapeutic programs."

About Delenex Therapeutics AG

Delenex is a privately-held biopharmaceutical company focused on the development of locally and systemically applied antibody therapeutics. Delenex aims at extending the benefits of proven antibody therapeutics to a much larger number of people suffering from psoriasis, hidradenitis suppurativa, acne and other, dermatological and non-dermatologic, diseases. Delenex' proprietary PENTRA^(R)Bodies are small, highly potent and stable antibody fragments that are superior in penetrating tissues and in crossing barriers in the human body.
Delenex was founded in September 2009 as a spin-off from ESBATech (now a Novartis company).

For further details please contact:

Jakob Schlapbach, CFO
Delenex Therapeutics AG
Wagistrasse 27
CH-8952 Schlieren
Phone: +41 44 730 5180
E-mail: jakob.schlapbach@delenex.com
Website: www.delenex.com